Hansa Biopharma AB (publ) (HNSBF)
USD 2.83
(0.0%)
USD 2.83
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 134.09 Million SEK | -13.22% |
| 2022 | 154.52 Million SEK | 356.12% |
| 2021 | 33.87 Million SEK | 455.56% |
| 2020 | 6.09 Million SEK | 81.27% |
| 2019 | 3.36 Million SEK | 0.18% |
| 2018 | 3.35 Million SEK | -2.44% |
| 2017 | 3.44 Million SEK | 33.46% |
| 2016 | 2.57 Million SEK | -52.54% |
| 2015 | 5.43 Million SEK | 15.22% |
| 2014 | 4.71 Million SEK | 173.07% |
| 2013 | 1.72 Million SEK | -34.05% |
| 2012 | 2.61 Million SEK | 104.24% |
| 2011 | 1.28 Million SEK | -71.17% |
| 2010 | 4.44 Million SEK | 49.08% |
| 2009 | 2.98 Million SEK | 2777.99% |
| 2008 | 103.67 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 55.98 Million SEK | 11.05% |
| 2024 Q3 | 48.66 Million SEK | 41.74% |
| 2024 Q2 | 34.33 Million SEK | -38.67% |
| 2023 Q3 | 22.83 Million SEK | -37.69% |
| 2023 Q4 | 50.41 Million SEK | 120.74% |
| 2023 FY | 134.09 Million SEK | -13.22% |
| 2023 Q1 | 24.19 Million SEK | -21.36% |
| 2023 Q2 | 36.65 Million SEK | 51.49% |
| 2022 FY | 154.52 Million SEK | 356.12% |
| 2022 Q2 | 26.39 Million SEK | -12.83% |
| 2022 Q3 | 67.08 Million SEK | 154.14% |
| 2022 Q4 | 30.76 Million SEK | -54.14% |
| 2022 Q1 | 30.28 Million SEK | 96.65% |
| 2021 FY | 33.87 Million SEK | 455.56% |
| 2021 Q4 | 15.39 Million SEK | 211.26% |
| 2021 Q3 | 4.94 Million SEK | 9.08% |
| 2021 Q2 | 4.53 Million SEK | -49.6% |
| 2021 Q1 | 8.99 Million SEK | 135.06% |
| 2020 Q1 | 885 Thousand SEK | -26.43% |
| 2020 FY | 6.09 Million SEK | 81.27% |
| 2020 Q3 | 762 Thousand SEK | 22.31% |
| 2020 Q2 | 623 Thousand SEK | -29.6% |
| 2020 Q4 | 3.82 Million SEK | 402.36% |
| 2019 Q4 | 1.2 Million SEK | 84.51% |
| 2019 FY | 3.36 Million SEK | 0.18% |
| 2019 Q1 | 917 Thousand SEK | -33.84% |
| 2019 Q2 | 592 Thousand SEK | -35.44% |
| 2019 Q3 | 652 Thousand SEK | 10.14% |
| 2018 Q3 | 484 Thousand SEK | -46.22% |
| 2018 Q1 | 588 Thousand SEK | -41.95% |
| 2018 Q2 | 900 Thousand SEK | 53.06% |
| 2018 FY | 3.35 Million SEK | -2.44% |
| 2018 Q4 | 1.38 Million SEK | 186.36% |
| 2017 Q3 | 678 Thousand SEK | -2.16% |
| 2017 Q4 | 1.01 Million SEK | 49.41% |
| 2017 FY | 3.44 Million SEK | 33.46% |
| 2017 Q1 | 1.05 Million SEK | 11.13% |
| 2017 Q2 | 693 Thousand SEK | -34.5% |
| 2016 Q2 | 542 Thousand SEK | 0.0% |
| 2016 Q4 | 952 Thousand SEK | 75.32% |
| 2016 FY | 2.57 Million SEK | -52.54% |
| 2016 Q3 | 543 Thousand SEK | 0.18% |
| 2016 Q1 | 542 Thousand SEK | 2.46% |
| 2015 FY | 5.43 Million SEK | 15.22% |
| 2015 Q4 | 529 Thousand SEK | 0.0% |
| 2015 Q3 | 529 Thousand SEK | 0.0% |
| 2015 Q2 | 529 Thousand SEK | -86.25% |
| 2015 Q1 | 3.84 Million SEK | 18.19% |
| 2014 Q2 | 349 Thousand SEK | -78.35% |
| 2014 Q4 | 3.25 Million SEK | 0.0% |
| 2014 Q1 | 1.61 Million SEK | 189.26% |
| 2014 FY | 4.71 Million SEK | 173.07% |
| 2014 Q3 | - SEK | -100.0% |
| 2013 FY | 1.72 Million SEK | -34.05% |
| 2013 Q2 | 338.21 Thousand SEK | 0.0% |
| 2013 Q3 | 557.28 Thousand SEK | 64.77% |
| 2013 Q4 | 557.28 Thousand SEK | 0.0% |
| 2012 FY | 2.61 Million SEK | 104.24% |
| 2011 FY | 1.28 Million SEK | -71.17% |
| 2010 FY | 4.44 Million SEK | 49.08% |
| 2009 FY | 2.98 Million SEK | 2777.99% |
| 2008 FY | 103.67 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -750.149% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -760889.728% |
| SQZ Biotechnologies Company | 21.47 Million USD | -524.332% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -636.052% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -9.06% |
| Mesoblast Limited | 5.9 Million USD | -2172.009% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Genus plc | 668.8 Million USD | 79.95% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -32592.697% |
| Marizyme, Inc. | 645.81 Thousand USD | -20663.692% |
| ContraFect Corporation | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -174590.272% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -203913.51% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -339223.852% |
| MultiCell Technologies, Inc. | 49.32 USD | -271885544.769% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -169.693% |
| EV Biologics, Inc. | 48.9 Thousand USD | -274120.859% |
| Q BioMed Inc. | 284.35 Thousand USD | -47057.748% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -353.066% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 45.338% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -191462.857% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -135356.694% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -176982.563% |
| IMV Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -20263.554% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.087% |
| Halberd Corporation | 999.00 USD | -13422722.823% |
| Enzolytics Inc. | 52.79 Thousand USD | -253885.15% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -9695.033% |
| SYBLEU INC | 11.69 Thousand USD | -1146394.528% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -21935.906% |
| argenx SE | 1.22 Billion USD | 89.065% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -6840.683% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -21619.708% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 84.027% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 7.585% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -23943.679% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -13339.962% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -177.317% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -703.66% |
| ONE Bio Corp. | 52.29 Million USD | -156.412% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -56584.985% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -56584.985% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -95516.149% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -28205.997% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -1621.582% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -1031392.308% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -339086.523% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -3926.847% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -1911.913% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -12806.064% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -420.41% |
| CSL Limited | 14.8 Billion USD | 99.094% |
| Cellectis S.A. | 755 Thousand USD | -17660.795% |